Llixadencel is under clinical development by Mendus and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Llixadencel’s likelihood of approval (LoA) and phase transition for Gastrointestinal Stromal Tumor (GIST) took place on 12 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Llixadencel Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Llixadencel overview

Ilixadencel is under development for the prevention of metastatic renal cell carcinoma (RCC), hepatocellular carcinoma, gastrointestinal stromal tumor (GIST), HPV-positive or HPV-negative squamous cell carcinoma of the head and neck, non-small cell lung cancer, gastric, adenocarcinoma of the gastroesophageal Junction and colon carcinoma. The drug candidate is administered intratumorally. The vaccine candidate is based on COMBIG (Combined Toll like Receptor Interferon-Gamma) platform.

The drug candidate was under development for melanoma (first and second), brain metastasis, squamous cell carcinoma of the head and neck, non-small cell lung cancer, gastric and gastroesophageal junction adenocarcinoma.

Mendus overview

Mendus, formerly Immunicum, develops allogeneic and off-the-shelf cell-based therapies for treating solid tumors. The company’s product candidate ilixadencel, an intratumoral immune primer is used for the treatment of renal cell cancer, gastrointestinal stromal tumors, multiple solid tumors, kidney, liver and hepatocellular cancer. Mendus another product DCP-001 is a cancer relapse vaccine that is derived from the DCOne leukemic cell line to treat acute myeloid leukemia and ovarian cancer. The company works in partnership with academic research groups, pharmaceutical and biotech companies to develop and commercialize new therapeutics. It operates a research and development facility at Leiden, The Netherlands. Mendus is headquartered in Stockholm, Sweden.

Quick View Llixadencel LOA Data

Report Segments
  • Innovator
Drug Name
  • Llixadencel
Administration Pathway
  • Intratumor
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.